Fact-checked by Grok 2 weeks ago

Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is an American multinational medical technology company founded in 1979 by and Peter Nicholas and headquartered in . The company designs, develops, manufactures, and markets innovative medical devices for minimally invasive procedures addressing unmet needs in areas such as , , peripheral interventions, , and . Boston Scientific's core segments include cardiovascular solutions like drug-eluting stents, implantable cardioverter-defibrillators, and left atrial appendage closure devices such as the system, alongside tools including single-use duodenoscopes and therapies for . The firm has pioneered advancements in , beginning with steerable catheters and balloons in the late , and continues to invest heavily in , launching nearly 90 products in 2023 alone while maintaining a pipeline supported by mergers, acquisitions, and clinical trials generating over 60 studies annually. These efforts have enabled treatments for over 44 million patients worldwide in recent years, positioning the company as a high-growth entity with operations spanning multiple continents and a focus on operational efficiency to drive . The company has achieved notable milestones, including the development of the drug-eluting stent system, which addressed restenosis challenges in coronary interventions, though it later prompted recalls due to balloon deflation issues linked to injuries and fatalities. Boston Scientific has also expanded through strategic acquisitions and faced defining legal challenges, particularly over transvaginal mesh devices marketed for and stress , leading to multistate settlements exceeding $189 million for alleged misrepresentations of safety risks such as and organ erosion. More recent issues include a 2024 recall of certain pacemaker models due to manufacturing defects and resolutions of disputes with competitors like . These events underscore the risks inherent in innovation, where empirical clinical data and regulatory scrutiny play critical roles in balancing patient outcomes against potential adverse events.

History

Founding and Early Development (1979–1991)

Boston Scientific Corporation was founded on June 29, 1979, in Watertown, Massachusetts, by John Abele, a physicist with prior involvement in medical device development, and Peter Nicholas, a former pharmaceutical executive with an MBA from the Wharton School. The two met while watching their children play soccer and formed the company as a holding entity to acquire Medi-Tech, Inc., a small firm Abele had collaborated with since the late 1960s, which specialized in minimally invasive surgical tools. They purchased Medi-Tech from Cooper Laboratories, starting with fewer than 50 employees and focusing on engineering advancements in catheter technologies to enable precise, less invasive vascular interventions over traditional open surgery. Early development centered on Medi-Tech's foundational innovations, including steerable catheters that allowed directional control during procedures and balloon catheters for dilating narrowed vessels, initially applied in areas like gall bladder surgery and later angioplasty. These devices stemmed from iterative engineering refinements, such as improving material flexibility and balloon inflation mechanics to compress arterial plaque via mechanical force, validated through preclinical testing rather than unproven assumptions. Despite initial skepticism from established medical firms favoring surgical standards, the company prioritized empirical validation of device efficacy in restoring blood flow, navigating FDA regulatory approvals for Class II and III devices that demanded rigorous safety data amid evolving standards for interventional cardiology tools. First-year revenues reached approximately $2 million, driven by these core products. Through the 1980s, Boston Scientific expanded via internal R&D investments and selective acquisitions of niche firms to bolster its portfolio, achieving revenues of $33 million by 1987 and profitability as sales scaled with clinician adoption of minimally invasive techniques. Pre-IPO financing relied on reinvested earnings and personal capital from founders, avoiding heavy venture dependence in an era when medtech startups faced limited external funding options, while sustaining growth amid challenges like and from incumbents doubting catheter durability. By 1991, annual sales hit $230 million with net earnings of $42 million, positioning the firm for public markets through demonstrated operational viability in cardiology-focused devices.

Initial Public Offering and Expansion (1992–2005)

Boston Scientific completed its initial public offering on May 19, 1992, issuing 23.5 million shares at $17 per share and raising approximately $400 million to support research, development, and acquisitions. The proceeds facilitated rapid portfolio diversification, with the company's stock experiencing significant appreciation driven by advancements in coronary stent technology. Key acquisitions marked this period's expansion, including the 1995 merger with SCIMED Life Systems, which enhanced capabilities in balloon catheters and stents following review. Subsequent deals, such as Target Therapeutics for $1.1 billion in 1997, strengthened neurovascular offerings, while the $2.1 billion acquisition of Schneider Worldwide in 1998 added vascular intervention products. The 2001 purchase of Cardiac Pathways for $115 million provided initial entry into , focusing on treatments. Innovations like the NIR ON Ranger coronary , approved by the FDA on August 13, 1998, positioned Boston Scientific as a leader in bare-metal stents, precursors to drug-eluting models. This was followed by FDA clearance for the paclitaxel-eluting stent on March 5, 2004, advancing restenosis prevention through polymer-based . expanded substantially, from $2.84 billion in to $6.28 billion in , with international sales comprising about one-third of by the mid-1990s amid growing global penetration.

Guidant Acquisition and Post-Merger Integration (2006–2010)

On January 25, 2006, Boston Scientific announced a merger agreement to acquire Corporation for approximately $27 billion, consisting of $42 in cash and $38 in Boston Scientific stock per Guidant share, valued at $80 per share. This deal emerged from a competitive bidding process, as Guidant had previously agreed to merge with but terminated that agreement to accept Boston Scientific's higher offer, prompting subsequent litigation from alleging . The acquisition aimed to bolster Boston Scientific's portfolio in cardiac rhythm management () devices, including pacemakers and (ICDs), complementing its existing interventional cardiology strengths. To secure regulatory approval amid antitrust concerns over combined market shares in stents and ICDs, Boston Scientific agreed to divest Guidant's vascular intervention and endovascular businesses to for $4.1 billion in cash plus potential milestone payments. The U.S. conditionally approved the transaction on April 20, 2006, requiring these divestitures to preserve competition in drug-eluting stents, where the merger would have otherwise created excessive concentration. The merger closed on April 21, 2006, creating a diversified leader in medical devices with enhanced capabilities. Post-merger integration focused on combining technologies, yielding R&D synergies and operational efficiencies that addressed inventory overlaps between overlapping product lines. The addition of Guidant's assets elevated Boston Scientific to the second-largest player in the ICD market behind , facilitating gains through unified innovation pipelines. By , these efforts supported diversified revenue streams, reducing reliance on stents amid market pressures. The acquisition incurred significant financial strain, including a credit rating downgrade to BBB by Fitch Ratings due to elevated debt levels exceeding $29 billion post-closing. Integration challenges, such as harmonizing supply chains and addressing product redundancies, were mitigated through cost-reduction initiatives and operational streamlining, laying groundwork for long-term efficiencies despite initial losses reported in .

Recent Growth and Strategic Moves (2011–Present)

Following the post-recession period, Boston Scientific pursued strategic acquisitions to bolster its portfolio in interventional and , beginning with the $4.2 billion acquisition of BTG plc in August 2019, which enhanced capabilities in vascular and oncology therapies despite subsequent divestiture of its specialty pharmaceuticals unit in December 2020. This move diversified revenue streams amid recovering elective procedure volumes, contributing to sustained organic net sales growth exceeding 10% annually in subsequent years. The disrupted elective procedures in early 2020, prompting adaptations and prioritization of essential cardiovascular interventions, yet the company achieved a rebound with double-digit organic growth resuming by mid-2021 as hospitals restored volumes. For instance, second-quarter organic net sales grew 11.6%, driven by elevated procedure adoption in and structural heart segments. This resilience supported broader portfolio expansion, including the $3.7 billion acquisition of Axonics, Inc., completed on November 15, 2024, which integrated sacral technologies for urinary dysfunction, targeting underserved pelvic health markets. In February 2025, Boston Scientific settled longstanding patent disputes with via a $1.725 billion payment, resolving over a dozen cases and eliminating ongoing litigation burdens to redirect resources toward innovation. Concurrently, the company expanded into emerging markets, where operational net sales grew 19.6% in , fueled by procedure volume increases in regions like and amid rising demand for minimally invasive therapies. Digital health integrations, such as AI-enabled and automated solutions, further supported this growth by enhancing procedure efficiency and patient monitoring. These initiatives underscored a focus on high-growth segments, with third-quarter 2025 cardiovascular procedures reflecting continued volume expansion.

Business Segments and Products

Interventional Cardiology and Rhythm Management

Boston Scientific's interventional cardiology offerings center on coronary stents and structural heart devices, with the SYNERGY™ XD Everolimus-Eluting Platinum Chromium Coronary Stent System serving as a flagship drug-eluting stent featuring a bioabsorbable polymer coating, thin struts (74 μm), and abluminal everolimus release to facilitate rapid endothelialization and minimize vessel wall exposure to permanent materials. This design addresses limitations of durable polymer stents by reducing risks of chronic inflammation, neoatherosclerosis, and late stent thrombosis, while clinical data demonstrate drug-eluting stents like SYNERGY achieve approximately 60% lower clinical restenosis rates compared to bare-metal stents in long-term follow-up. The company's TAVR portfolio previously included the ACURATE neo2™ Aortic Valve System, a self-expanding transcatheter heart valve with Active PVseal™ technology and an extended sealing skirt to reduce paravalvular leak, though worldwide sales were discontinued in May 2025 following regulatory hurdles in key markets. In cardiac rhythm management, Boston Scientific emphasizes defibrillators and pacemakers for control, including the EMBLEM™ MRI S-ICD System, a subcutaneous that delivers shocks for ventricular arrhythmias without transvenous leads, thereby avoiding endovascular complications such as infection, lead fracture, and venous occlusion reported in up to 10-20% of traditional ICD cases over long-term use. This leadless approach, combined with MRI compatibility and algorithms for oversensing mitigation, supports protection against with cumulative data spanning over two decades of subcutaneous ICD utilization. The portfolio also encompasses CRT-D devices for resynchronization in patients with dyssynchrony, alongside ICDs that have demonstrated causal survival benefits, including a 24.3% relative reduction in all-cause mortality for primary prevention indications in meta-analyses of randomized trials. Pacemaker technologies include the ACCOLADE™ MRI Pacing Systems, featuring 1.6 Ah electrolytic batteries projected to last 9.5 to 16.7 years depending on pacing dependency and monitoring frequency, with automatic daily trending for /fibrillation burden and activity levels to optimize therapy. Advancements in leadless options, such as the EMPOWER™ Leadless integrated into a modular system with the S-ICD, enable on-demand ventricular pacing and antitachycardia pacing via wireless communication, further diminishing lead-related infection risks—estimated at 1-2% annually with transvenous systems—while maintaining high communication success rates in clinical evaluations. These devices contribute to Scientific's dominant position in U.S. cath lab procedures for , where reduced restenosis and management directly correlate with improved patency and event-free survival in cohorts.

Endoscopy, Urology, and Pelvic Health

Boston Scientific's division develops devices for gastrointestinal procedures, emphasizing single-operator systems that enhance visualization and therapeutic precision during (ERCP). The DS Direct Visualization System facilitates cholangioscopy with high-resolution , enabling targeted and stone management; clinical data indicate stone clearance rates of 59% to 90% per session, with overall clearance achieving 72% to 95%. In one multicenter study, it demonstrated a 92% procedural success rate for stone extraction in cases where conventional ERCP failed, often in a single session. Resolution 360 clips provide mechanical for upper bleeding control, deploying through endoscopes to achieve secure closure with rotational adjustability, thereby supporting minimally invasive alternatives to . In , the company offers -based therapies and ureteroscopy tools for (BPH) and stone disease, prioritizing outpatient feasibility and reduced recovery times. The XPS Laser Therapy System, a 180W 532nm , vaporizes tissue for BPH relief, with studies showing shorter hospital stays (often same-day discharge) and catheterization times compared to (TURP), alongside lower bleeding risks. The LithoVue Elite single-use digital flexible ureteroscope integrates intrarenal pressure monitoring for kidney stone visualization and fragmentation, allowing real-time adjustments to minimize procedural complications like pressure-related tissue damage during . The Pelvic Health portfolio addresses female and through sling systems and , adapting to regulatory scrutiny on synthetic meshes by emphasizing mid-urethral slings and nerve stimulation. The Ultra Sling Family features adjustable slings for stress urinary incontinence, designed for precise tensioning to optimize continence outcomes with reduced risks via tissue integration properties. Following the 2024 acquisition of Axonics, via the Axonics system delivers chronic electrical impulses to modulate pelvic nerves, offering rechargeable implants with reported improvements in urgency incontinence episodes and lower reoperation rates than traditional batteries. Advanced in these segments, such as integrated scopes and pressure sensors, correlates with procedural efficiencies, including lower complication incidences from enhanced anatomical targeting over blind or generic techniques.

Neuromodulation and Specialty Therapies

Boston Scientific's portfolio centers on implantable devices that deliver targeted electrical stimulation to disrupt aberrant neural signaling in conditions such as and , leveraging principles of bioelectric modulation to restore physiological balance in neural circuits. The Vercise (DBS) system, approved for bilateral subthalamic nucleus stimulation as an adjunct to levodopa in advanced , features directional leads and adaptive programming via Image Guided Programming software to optimize targeting of pathways. In the INTREPID , a multicenter, double-blind with controls, Vercise DBS yielded a 51% improvement in Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) motor scores off medication, surpassing outcomes (p<0.001), with sustained benefits in and metrics at 12 weeks. The Vantage reported a mean 62.6% UPDRS-III improvement (p<0.0001), demonstrating directional steering's role in minimizing side effects while enhancing motor function through precise current fractionalization across multiple contacts. Investigational applications extend to , where Vercise leads have facilitated multitarget thalamic DBS in drug-resistant cases, achieving seizure frequency reductions in small cohorts via anterior nucleus and centromedian targeting, though lacking FDA approval for this indication. For management, Boston Scientific offers rechargeable and non-rechargeable Spinal Cord Stimulation () systems, including the WaveWriter Alpha and Spectra WaveWriter platforms, indicated for intractable trunk and limb resistant to conservative . These devices employ multiple waveforms—such as paresthesia-free sub-perception stimulation and FAST —for personalized coverage via up to 32 contacts, aiming to gate nociceptive transmission in the dorsal horn. The SOLIS compared WaveWriter SCS against conventional medical management in patients with without prior spine surgery, showing 90% of SCS patients achieving ≥50% reduction at 3 months without escalation, sustained in 84% at 1 year, versus 8% in controls (p<0.001). Real-world data indicate SCS reduces utilization by 50-70% in responders, correlating with improved function and lower healthcare costs, as electrical modulation interrupts central pathways more effectively than alone. Compared to reoperation or continued , SCS yields incremental quality-adjusted life years (QALYs) at cost-effectiveness ratios below $20,000 per QALY gained in long-term analyses. Specialty therapies include agents for interventions, such as Obsidio Conformable Embolic and DC Bead microspheres, designed to occlude hypervascular tumors by injecting liquid or loadable particles that conform to vasculature, halting nutrient supply and inducing . Obsidio, a hydrogel-based agent, polymerizes for precise, permanent in arteriovenous malformations and hepatic tumors, with preclinical showing 95% vessel penetration and recanalization resistance superior to traditional coils. These target causal tumor growth drivers——via mechanical blockade, outperforming systemic in local control for , with meta-analyses reporting 80-90% response rates in embolization cohorts. Additionally, the FARAPULSE pulsed field system employs non-thermal electrical pulses to selectively ablate cardiac tissue in by exploiting differentials between myocardial and esophageal cells, achieving 77.5% 1-year freedom from in the MANIFEST-PF registry without esophageal injury. This bioelectric approach minimizes compared to , supporting its role in rhythm disorders through irreversible pore formation in membranes.

Innovations and Research

Key Technological Advancements

Boston Scientific pioneered technology with the stent system, which utilized a durable coating to deliver , an immunosuppressant that inhibits cell proliferation to prevent restenosis following . The kinetics relied on a controlled-release from the matrix, where the diffuses into the vessel wall over weeks to months, balancing therapeutic concentration with minimization of from the permanent . This evolved into everolimus-eluting platforms like PROMUS and , where —a analog with enhanced —enabled more uniform tissue penetration and reduced peak levels, addressing limitations in delivery such as variable absorption. The bioabsorbable polymer stent, approved by the FDA in 2015, further refined this by employing an abluminal coating on a bioabsorbable polymer that degrades within three to four months post-implantation, facilitating complete endothelial coverage and vessel healing without residual foreign material. This design leverages thinner platinum-chromium struts (74 microns) for improved deliverability and radial strength, with the polymer's hydrolysis-driven breakdown eliminating long-term risks inherent in durable polymers. In cardiac , the FARAPULSE pulsed field (PFA) system represents a shift from to non-thermal , delivering ultra-short, high-voltage electrical s via basket and flower catheters to create irreversible pores in cell membranes, selectively targeting cardiomyocytes while sparing adjacent structures like the and due to differential tissue sensitivities. This engineering minimizes collateral thermal damage by avoiding heat conduction, with waveform optimization over a ensuring precise formation through controlled duration and . The EMPOWER leadless , introduced as part of the modular cardiac rhythm management (mCRM) system, features a catheter-deliverable device implanted directly in the right ventricle, communicating wirelessly with a subcutaneous (S-ICD) to enable on-demand pacing or antitachycardia therapy without transvenous leads. Its engineering foundation includes a helical for fixation, onboard battery for up to nine years of service, and inductive communication protocols that reduce mechanical failure points associated with traditional lead-based systems. Boston Scientific integrates artificial intelligence into intravascular imaging via the AVVIGO+ multi-modality guidance system, which automates analysis of high-definition intravascular ultrasound (IVUS) and optical coherence tomography (OCT) data for real-time procedural navigation, enhancing lesion assessment through algorithmic edge detection and vessel geometry mapping. This AI-driven processing streamlines image interpretation by applying machine learning models trained on physiological datasets, providing quantitative metrics for stent optimization without manual calibration delays.

Clinical Trials and Evidence-Based Outcomes

Boston Scientific's subcutaneous (S-ICD) systems have shown comparable efficacy to transvenous ICDs in preventing sudden cardiac death, with significantly lower rates of lead- and pocket-related complications. In the randomized trial, S-ICD implantation resulted in a of 0.63 for major complications compared to transvenous ICDs (95% CI 0.44-0.90, p=0.01), while success rates exceeded 98% in both arms. Pooled data from the study and EFFORTLESS registry reported a 2-year all-cause of 3.2%, consistent with broader meta-analyses of ICD primary prevention demonstrating mortality hazard ratios of approximately 0.80 in patients with left ventricular ≤35%. These outcomes underscore aggregate survival benefits, with quality-adjusted life years gained outweighing rare device failures in large cohorts. In , the FARAPULSE pulsed field system achieved primary safety and effectiveness endpoints in the phase I ADVANTAGE AF trial for drug-refractory paroxysmal , with a 12-month freedom from recurrence rate of 73.3% and major complication rate of 0.7%. Similarly, the WATCHMAN FLX left atrial appendage closure device demonstrated superior bleeding risk reduction compared to direct oral anticoagulants in the OPTION randomized trial, meeting the primary efficacy endpoint of reduced all-cause mortality, , or systemic at 36 months (HR 0.69, p=0.04 for bleeding superiority). Post-market surveillance for S-ICD systems indicates 30-day complication rates below 4%, reinforcing a favorable risk-benefit profile across thousands of implants. For peripheral interventions, the Ranger drug-coated balloon maintained primary patency rates near 90% at one year in the randomized COMPARE trial against uncoated balloons, with low rates of revascularization. In coronary applications, three-year outcomes from PROMUS everolimus-eluting stents showed sustained low rates of failure (around 10%), comparable to devices in pooled analyses. While selective emphasis on isolated adverse events occurs, from these trials privileges overall reductions in mortality and morbidity, with major complication incidences typically under 1% in aggregated real-world data, supporting net clinical utility over in indicated populations.

Financial Performance

Historical Revenue and Market Position

Boston Scientific's annual revenue grew from $2.66 billion in 2000 to $16.74 billion in 2024, reflecting a exceeding 8% over the period, primarily fueled by expansions in its portfolio amid rising demand for cardiovascular interventions linked to aging populations and procedural volumes. This trajectory included significant jumps following key acquisitions, such as the 2006 purchase of Corporation, which integrated advanced rhythm management and defibrillator technologies, boosting revenue from $6.28 billion in 2005 to $7.82 billion in 2006. While acquisitive strategies accounted for a substantial portion of early growth—evident in revenue accelerations during merger integrations—organic contributions became more pronounced post-2010, supported by innovations in stents and devices that captured share in high-volume procedures. In market positioning, Boston Scientific established itself as a leader in , outpacing peers like in segment-specific growth rates despite Medtronic's larger overall scale ($32 billion revenue in recent years versus Boston Scientific's $16.7 billion in 2024). Its expanded from approximately $10.6 billion in 1998 to over $149 billion by 2024, placing it among the top-tier medtech firms by valuation, with return on invested capital (ROIC) stabilizing around 7-9% in recent assessments, indicative of disciplined capital allocation following merger synergies and operational efficiencies. EBITDA margins improved from lower teens in the early 2000s to approximately 25% by 2023 ($3.6 billion EBITDA on $14.24 billion revenue), driven by scale economies in manufacturing and supply chain optimizations that offset pressures from regulatory and litigation costs in the device sector. This margin expansion underscored effective cost management amid demographic-driven procedure increases, countering narratives of inherent inefficiencies in capital-intensive medtech environments.

Recent Earnings and Projections (2020–2025)

In 2024, Boston Scientific reported full-year net sales of $16.747 billion, reflecting 17.6% reported growth and 16.4% compared to the prior year, driven by increased volumes and contributions from recent acquisitions. For the third quarter of 2025 ended September 30, net sales reached $5.06 billion, marking 20.3% reported growth and 15.3% year-over-year, with GAAP of $0.51. Adjusted earnings per share for the quarter stood at $0.75, up 19% from the year-ago period. Reported growth in this period outpaced organic figures primarily due to acquisitions, including the November 2024 closure of the $3.7 billion deal for Axonics, Inc., which bolstered offerings, and the September 2024 acquisition of Silk Road Medical, Inc., while organic expansion stemmed from post-pandemic procedure recovery and strong demand for core products like cardiovascular devices. The company raised its full-year 2025 organic growth guidance to 15.5%, citing momentum in and left atrial appendage technologies, alongside sustained procedural uptake. Looking forward, Boston Scientific anticipates full-year 2025 reported growth of approximately 20%, with adjusted guidance lifted to $3.02–$3.04, implying 20–21% growth, supported by advancements and regulatory approvals. Management projects a trajectory toward $25.4 billion in annual by , underpinned by above-market organic expansion and strategic bolt-ons, while robust cash flows have facilitated share repurchases, increases, and debt management stability following litigation resolutions.

Legal and Regulatory Challenges

Patent Disputes and Settlements

Boston Scientific has engaged in numerous patent disputes, primarily in and , reflecting the competitive landscape in innovation. These cases often involve stents, implantable cardioverter-defibrillators (ICDs), and stimulation technologies, with outcomes including jury verdicts, appeals, and settlements that balance litigation costs against ongoing product commercialization. A protracted series of lawsuits with (J&J), dating to 2003, centered on overlapping patents for designs and related technologies, including Boston Scientific's Jang and J&J's Palmaz and Gray s. Mixed judicial outcomes ensued, such as a 2025 appeals court affirmation that J&J's BX Velocity and stents infringed a valid Boston Scientific , alongside prior findings of infringement in both directions. The disputes culminated in a February 1, 2025, where Boston Scientific agreed to pay J&J $1.725 billion, resolving over a dozen cases and allowing continued marketing of existing lines without further injunctions. In , Boston Scientific settled claims with Nevro Corp. in August 2022 over stimulation technologies for management, paying $85 million and granting Nevro a worldwide, non-exclusive under Boston Scientific's asserted families. The agreement included a cross- for paresthesia-free therapy products, dismissing all related U.S. district court and Trial and Appeal Board proceedings. Boston Scientific faced an adverse ruling in a 2023 dispute with TissueGen and the University of Texas over for coatings in drug-eluting stents. A federal jury found on January 31, 2023, that Boston Scientific's stents infringed TissueGen's '296 , awarding $42 million in lost royalties after determining willful induced infringement. This verdict highlighted vulnerabilities in technologies central to everolimus-eluting stents. Boston Scientific has also secured defenses and wins, such as a court dismissal of J&J's claims that its infringed Cordis patents, upholding non-infringement and invalidity findings on appeal. These successes, alongside settlements, underscore patents as strategic assets where litigation expenses—often exceeding hundreds of millions—represent calculated business trade-offs to prioritize empirical advancements in over prolonged battles.

Product Recalls and Safety Concerns

In April 2024, the U.S. (FDA) announced a recall of Boston Scientific's Obsidio Conformable Embolic, a hydrogel-based device used for peripheral vasculature applications including hypervascular tumors and bleeding. The action stemmed from risks of unintended embolic migration leading to bowel ischemia, particularly when deployed for , with reported adverse events including 15 injuries and at least two deaths by October 2024. Root causes were traced to delivery system inconsistencies and material conformance issues under certain procedural conditions, prompting Boston Scientific to issue updated physician instructions for microcatheter preparation and deployment techniques rather than physical product removal. Post-recall enhancements included refined protocols and expanded warnings, with no further widespread incidents documented after implementation. Boston Scientific's family of pacemakers faced a manufacturing-related initiated in December 2024 for a subset of devices exhibiting high internal cell impedance (HICI) in batteries, which could premature to a low-power safety mode and necessitate early replacement. Affecting over one million units, the issue arose from variances in assembly leading to accelerated impedance rise, potentially compromising pacing functionality; the FDA upgraded it to Class I status—the agency's most severe classification—in February 2025 due to risks of serious injury or death from device failure. Remediation involved software updates to impedance and alert for elective replacement, alongside enhanced quality controls in production; by October 2025, follow-up notices emphasized physician monitoring to mitigate progression to permanent safety mode. Historical recalls of Boston Scientific's (ICD) components, particularly ENDOTAK RELIANCE leads in the , addressed concerns over insulation breaches and conductor fractures from mechanical stress or inconsistencies. An FDA I designation was applied to certain lots in September 2025 for similar lead integrity risks, building on prior advisories. However, large-scale studies reveal low overall rates, with non-recalled ICD leads showing approximately 2.3% cumulative electrical dysfunction (annualized at 0.6%) and 10-year exceeding 98% in analyses. These incidents were predominantly linked to extrinsic factors like implant site rather than flaws, with post-recall data demonstrating improved lead durability through reinforced materials and rigorous testing, maintaining device reliability in broader populations.

Litigation and Settlements

![Implantable_cardioverter-defibrillator.jpg][float-right] Boston Scientific faced significant product liability litigation stemming from defects in implantable cardioverter-defibrillators (ICDs) acquired through its 2006 purchase of Guidant Corporation. Plaintiffs alleged that Guidant concealed known risks of device malfunctions, including short-circuiting and failure to deliver shocks, leading to injuries and deaths between 2002 and 2005. The company settled thousands of claims, including a $240 million agreement in 2007 covering over 8,500 patients affected by 2005-2006 recalls, and additional federal resolutions totaling approximately $972 million by 2013 for lawsuits and investigations related to these defective devices. In transvaginal mesh cases, Boston Scientific encountered lawsuits claiming inadequate warnings and design defects causing , erosion, and organ perforation. A notable Dallas jury verdict awarded $73.4 million to plaintiff Martha Salazar for negligence, later reduced to $34.6 million under Texas tort reform caps. These disputes culminated in a $188.6 million multistate in 2021 with 47 states and of Columbia over allegations of deceptive marketing, following FDA safety communications in highlighting serious complications and a 2016 order reclassifying devices as high-risk, effectively banning sales. While plaintiffs emphasized causal links between device flaws and patient harms unsupported by adequate disclosures, Boston Scientific defended its products as FDA-approved for specific indications with clinical evidence demonstrating benefits outweighing risks compared to surgical alternatives, which carry inherent complication rates up to 30% in peer-reviewed studies. Critics of the litigation volume, including policy analyses, argue that expansive claims foster overlitigation, driving defensive corporate practices and elevating costs—estimated at 2.5% of U.S. healthcare spending—ultimately borne by patients through higher premiums and prices, thereby complicating access to innovative therapies.

Corporate Governance and Culture

Leadership and Notable Executives

Michael F. Mahoney has served as chairman, president, and of Boston Scientific Corporation since November 2011, following his appointment as president in October of that year. Prior to assuming the CEO role, Mahoney led the company's international division from 2007 to 2010, where he implemented a growth strategy centered on product innovation, acquisitions, and global expansion. Under his , Boston Scientific has completed more than 40 acquisitions, contributing to revenue expansion from $7.3 billion in 2012 to $16.7 billion in 2024, alongside a that reached approximately $148 billion by late 2025. The company was co-founded in 1979 by John E. Abele and , who transformed an initial focus on minimally invasive medical technologies—stemming from Abele's prior work at Medi-Tech, Inc.—into a global enterprise through strategic partnerships and early acquisitions. , serving as CEO until 1999, emphasized entrepreneurial risk-taking and deal-making to scale the startup from fewer than 50 employees to a diversified medtech leader, while Abele contributed vision and later pursued in education and robotics via organizations like FIRST. passed away on May 14, 2022. Among notable executives, Daniel J. Brennan served as executive vice president and from 2014 until his retirement announcement in April 2025, overseeing financial strategies that supported acquisition-driven growth and operational efficiency during a period of sustained double-digit revenue increases. His tenure correlated with enhanced R&D investment, approximating 10% of sales, which bolstered in core segments like and .

Organizational Culture and Values

Boston Scientific's organizational culture is anchored in six core values: caring, meaningful , high , collaboration, , and winning spirit. These principles emphasize , patient-focused advancement, and a competitive that prioritizes results over proceduralism, fostering an where empirical outcomes in R&D and product development drive decision-making. Employee resource groups and collaborative spaces reinforce these values by promoting idea-sharing without mandated demographic targets, attributing innovation gains to varied perspectives emerging organically from merit selection. Internal metrics indicate a culture aligned with high performance, with ratings averaging 4.2 out of 5 and 84% of employees recommending the company, surpassing typical medtech sector averages around 3.9. Voluntary turnover rates have remained below 10% in recent years, at 7.1% in , reflecting retention tied to performance incentives and career mobility rather than retention quotas. This stability correlates with robust R&D output, including over 49,000 global patents—more than 45% granted—and recognition as one of America's most innovative companies in 2024, suggesting a meritocratic structure enhances productivity over ideologically driven diversity mandates. Critiques have centered on historical sales practices, where incentive structures encouraged off-label promotion and kickbacks, contributing to settlements like $22 million in 2011 for Guidant-related violations and $30 million in 2013 for defective device sales in Medicare patients. Ongoing probes, including a 2022 Foreign Corrupt Practices Act investigation in Vietnam prompted by whistleblowers, highlight persistent compliance risks in high-pressure sales environments. Post-scandal reforms include enhanced ethics training and a revised code of conduct emphasizing legal adherence, which have reportedly reduced violation incidents, though skeptics question if incentive realignments fully mitigate causal links to past ethical lapses.

Global Operations and Impact

Headquarters and Facilities

Boston Scientific's global headquarters is located at 100 Boston Scientific Way in , following the consolidation of operations from Natick completed in 2014. This state-of-the-art campus centralizes executive leadership, , and administrative functions to streamline and efforts. The facility supports core operational efficiencies by integrating proximity to the area's specialized workforce in medical technology. Key U.S. and operational hubs include the campus in , which focuses on cardiac rhythm management () devices such as implantable cardioverter-defibrillators and related components. This site, expanded with a 400,000-square-foot facility opened in October 2025, enhances production capacity for CRM technologies amid regional expertise in engineering. Internationally, the , , facility serves as a center, and exporting over four million cardiovascular devices annually, including stents and vascular products, to support efficient transatlantic supply logistics. These facilities are configured for , with strategic investments post-2020 to mitigate disruptions by expanding domestic manufacturing flexibility and end-to-end visibility. For instance, enhancements in bolster U.S.-based output, reducing reliance on global bottlenecks exposed during the . Locations in established medtech clusters like and Maple Grove facilitate access to skilled engineering talent, thereby accelerating product development cycles through localized expertise and collaboration.

International Expansion and Healthcare Contributions

Boston Scientific operates with commercial representation in 127 countries, supporting a global footprint that extends beyond its U.S. base to include manufacturing, R&D, and sales in regions such as , the , (EMEA), and (APAC). Expansion in EMEA has been marked by operational net sales growth of 13.8% in 2024 compared to 2023, driven by localized regulatory approvals for product portfolios in and . In APAC, growth has accelerated through market-specific strategies, including strong performance in and , where the company pursued acquisitions to bolster vascular and peripheral intervention capabilities. A notable example is the 2022 strategic investment acquiring a majority stake in Acotec Scientific Holdings, a Chinese firm specializing in drug-coated balloons and s, enhancing access to high-growth emerging markets. The company's medical devices contribute to healthcare by enabling treatments for over 44 million patients annually worldwide, facilitating minimally invasive procedures that shift care from inpatient to outpatient settings and thereby reducing overall system costs. In cardiovascular interventions, drug-eluting stents such as the platform have demonstrated superior efficacy over bare-metal stents in acute cases, with lower rates of target lesion revascularization and reduced ischemic outcomes in clinical trials like HORIZONS-AMI. These advancements align with broader declines in mortality since the widespread adoption of stenting in the , where coronary interventions have improved procedural safety and long-term patency compared to earlier surgical standards, though extensive stenting correlates with higher 10-year mortality risks relative to coronary artery bypass grafting in complex cases. Similarly, implantable cardioverter-defibrillators from Boston Scientific have supported sudden cardiac death prevention, contributing to extended longevity in high-risk populations through reliable management. Despite these benefits, access remains uneven in developing markets, where device costs and limitations create inequities, limiting adoption outside affluent regions and potentially widening disparities. Free-market dynamics, as exemplified by Boston Scientific's $1.68 billion annual R&D investment, have accelerated innovation cycles—evident in rapid iterations from bare-metal to drug-eluting technologies—outpacing equivalents in state-directed systems, which often face bureaucratic delays and reduced incentives for high-risk development. This private-sector approach has indirectly bolstered economic productivity by enabling healthier workforces and fewer disability-adjusted life years lost to cardiovascular events, though direct GDP attribution requires further econometric analysis beyond company-specific sales data.

References

  1. [1]
    History of Boston Scientific Corporation – FundingUniverse
    Medi-Tech Inc., partially owned by John Abele, introduces its first products, a family of steerable catheters. 1979: Boston Scientific is founded by John Abele ...
  2. [2]
    What is Brief History of Boston Scientific Company? - Matrix BCG
    Sep 10, 2025 · The company as we know it, Boston Scientific Corporation, was officially founded on June 29, 1979, by John Abele and Peter Nicholas in Watertown ...<|separator|>
  3. [3]
    About Our Global Headquarters, Marlborough MA - Boston Scientific
    Jul 3, 2014 · Boston Scientific Corporation recently established its new global headquarters in Marlborough, MA, on a state-of-the-art campus designed to drive global ...
  4. [4]
    Boston Scientific | BSX Stock Price, Company Overview & News
    Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties.
  5. [5]
    Business Overview – Boston Scientific | Advancing Science For Life
    Mar 21, 2024 · We are a growth company conditioned for high performance. Our goal is to create value for shareholders by delivering top tier revenue growth, expanding ...
  6. [6]
    [PDF] 2023 Annual Report - Boston Scientific Investor Relations
    Mar 20, 2024 · We launched nearly 90 products, fueled our pipeline with significant merger and acquisition developments, generated clinical evidence through 63 ...Missing: controversies | Show results with:controversies
  7. [7]
    [PDF] 2024 Annual Report - Boston Scientific
    Mar 19, 2025 · Most important, we helped improve the lives of more than 44 million patients around the world. While the company's biggest news of 2024 was our.Missing: controversies | Show results with:controversies
  8. [8]
    Boston Scientific in $189 million settlement with U.S. states ... - Reuters
    Mar 23, 2021 · The states accused Boston Scientific of concealing potential serious risks of using the devices, including chronic pain, urinary dysfunction and ...
  9. [9]
    AG Racine Announces $188.6 Million Multistate Settlement with ...
    Mar 22, 2021 · The settlement resolves allegations that Boston Scientific misrepresented the safety of these products by failing to disclose the full range of ...<|control11|><|separator|>
  10. [10]
    Boston Scientific Accolade Pacemaker Recall Lawsuit
    Boston Scientific issued a recall in December 2024 for certain Accolade pacemaker models after discovering a significant manufacturing defect.Why Are People Filing... · What Should I Do if I Have a...
  11. [11]
    Boston Scientific Settles Longstanding Patent Disputes With J&J
    Feb 1, 2025 · "In the past year, we have significantly reduced the volume of outstanding litigation, having now settled 17 lawsuits with J&J, as well as ...
  12. [12]
    Boston Scientific Corporation - Company-Histories.com
    Boston Scientific Corporation was founded in 1979 by John Abele and Peter Nicholas, who met while watching their children play soccer. Nicholas, a Wharton ...
  13. [13]
    In remembrance of our co-founder and former CEO, Pete Nicholas
    A dealmaker and entrepreneurial risk-taker, Pete and co-founder John Abele built Boston Scientific from a startup with fewer than 50 employees and financed with ...Missing: Herman | Show results with:Herman
  14. [14]
    Boston Scientific Co-founder John Abele Recognized by TCT ...
    Oct 12, 2015 · In 1979, Abele partnered with a former pharmaceutical executive, Peter Nicholas, to form Boston Scientific for the purpose of purchasing Medi- ...Missing: Herman | Show results with:Herman
  15. [15]
    Boston Scientific: Making the Most of Its First 25 Years
    Aug 1, 2004 · But that was not the case in 1979. Instead, John Abele, the president of the company and a minority shareholder of Medi-tech, teamed up with ...Missing: Herman | Show results with:Herman
  16. [16]
    BOSTON SCIENTIFIC CORPORATION - SEC.gov
    In 1979, John Abele joined with Peter Nicholas to form Boston Scientific Corporation, which indirectly acquired Medi-tech. This acquisition began a period ...<|separator|>
  17. [17]
    Boston Scientific Corp | Encyclopedia.com
    Early History: 1969–79. Boston Scientific Corporation was founded in 1979 by John Abele and Peter Nicholas, who met while watching their children play soccer.Missing: Herman | Show results with:Herman
  18. [18]
    Boston Scientific - 33 Year Stock Price History | BSX - Macrotrends
    An investor who bought $1,000 worth of Boston Scientific stock at the IPO in 1992 would have $22,617 today, roughly 23 times their original investment - a ...
  19. [19]
    Boston Scientific Corporation - Federal Trade Commission
    May 3, 1995 · ... Scientific Corporation, settling charges that its acquisition of Cardiovascular Imaging Systems, Inc.(CVIS) and SCIMED Life Systems, Inc.
  20. [20]
    Boston Scientific buys Cardiac Pathways - Providence Business News
    Boston Scientific Corp. announced that it was buying Cardiac Pathways Corp. of Sunnyvale, Calif. for $115 million.
  21. [21]
    Boston Scientific Gets FDA Approval for the NIR Coronary Stent
    Aug 13, 1998 · FDA has granted approval to Boston Scientific Corp. for the market release of the NIR ON Ranger Coronary Stent.Missing: introduction date
  22. [22]
    COMPANY NEWS; F.D.A. APPROVES BOSTON SCIENTIFIC STENT
    Mar 5, 2004 · Boston Scientific receives Food and Drug Administration approval to sell its Taxus drug-coated stent (S)
  23. [23]
    NYSE: BSX Boston Scientific Revenue - WallStreetZen
    2005-12-31, $6.28B, $659.00M, +11.72%. 2004-12-31, $5.62B, $2.15B, +61.80%. 2003-12 ... 2000-12-31, $2.66B, -$178.00M, -6.26%. 1999-12-31, $2.84B, $608.00M, + ...
  24. [24]
    Boston Scientific and Guidant Announce Signing of ... - SEC.gov
    Exhibit 99.1. Boston Scientific and Guidant Announce Signing of Merger Agreement Valued at $27 Billion. Natick, MA and Indianapolis, IN (January 25, 2006) ...Missing: details | Show results with:details
  25. [25]
    News Releases - Boston Scientific
    Mar 31, 2006 · On January 25, 2006, Boston Scientific and Guidant announced that they had entered into a merger agreement, under which Boston Scientific will ...Missing: details | Show results with:details
  26. [26]
    Boston Scientific Completes Combination with Guidant
    Boston Scientific Corporation (NYSE: BSX) today announced that it has completed its combination with Guidant Corporation (NYSE: GDT), creating a global leader ...Missing: R&D ICDs<|separator|>
  27. [27]
    FTC Requires Asset Divestitures Before Allowing Boston Scientifics ...
    Apr 20, 2006 · FTC Requires Asset Divestitures Before Allowing Boston Scientifics $27 Billion Acquisition of Guidant Corporation | Federal Trade Commission.
  28. [28]
    Boston Scientific Corporation Announces Agreement To Sell ...
    Jan 9, 2006 · "Our agreement with Abbott to divest Guidant's vascular intervention and endovascular businesses demonstrates our commitment to address ...
  29. [29]
    [PDF] printmgr file - Boston Scientific Investor Relations
    Oct 31, 2013 · both increase our market share in the existing ICD market and expand ... merger agreement between Johnson & Johnson and Guidant. (Merger ...
  30. [30]
    Boston Scientific swings to profit - MarketWatch
    Jul 20, 2007 · ... Guidant's stent business as part of that company's merger ... Guidant buyout, Boston Scientific is now the second-biggest marketer of ICDs.
  31. [31]
    Boston Scientific sees continued share gains in ICDs - Reuters
    May 28, 2009 · CHICAGO, May 28 (Reuters) - Boston Scientific sees more share gains in ICD market. * Boston Scientific sees industry growing in mid-single ...
  32. [32]
    Boston Scientific swings to profit - MarketWatch
    Jul 20, 2007 · Last year, Boston Scientific outbid Johnson & Johnson to buy Guidant for $27 billion in order to gain a foothold in the once-hot ICD market.
  33. [33]
    Fitch Downgrades Boston Scientific Corp. to 'BBB' After Guidant ...
    Apr 21, 2006 · Fitch Ratings has downgraded Boston Scientific Corp. (BSX) following today's completion of the company's $29 billion acquisition of Guidant Corp.Missing: integration 2006-2010 synergies
  34. [34]
    Boston Scientific Posts $4.26 Billion Loss - The New York Times
    Jul 28, 2006 · Boston Scientific's shares fell last week to their lowest level in more than four years amid concern about integrating Guidant. It gained 69 ...Missing: 2006-2010 | Show results with:2006-2010
  35. [35]
    Boston Scientific Closes Acquisition of BTG plc. - PR Newswire
    Aug 19, 2019 · The transaction is expected to be four to five cents accretive in 2020 on an adjusted basis, and increasingly accretive thereafter. On a GAAP ...
  36. [36]
    Boston Scientific Signs Definitive Agreement to Divest BTG Specialty ...
    Dec 1, 2020 · The agreement includes the transfer of five facilities and approximately 280 employees globally. The transaction is expected to close in the ...
  37. [37]
    Boston Scientific Provides Update on COVID-19 Impact and ...
    Apr 2, 2020 · The company is providing an update on the actions it has taken and a preliminary estimated revenue growth range for the first quarter 2020.
  38. [38]
    Interested in our Q2 2023 financial results? - Boston Scientific
    Jul 26, 2023 · Overall, we generated net sales of $3.599 billion during the second quarter of 2023, growing 11.6 percent on an organic basis[1] compared to the ...
  39. [39]
    Boston Scientific Closes Acquisition of Axonics, Inc.
    Nov 15, 2024 · The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter. On a GAAP basis, the ...
  40. [40]
    Expanding partnership - Operational Improvement in HPB
    We have partnered with the Boston Scientific HS&P team to create the ADVANTICS™ ezPro digital solution, that can enable your team to gain control and automation ...Missing: emerging | Show results with:emerging
  41. [41]
    Boston Scientific announces results for third quarter 2025
    MedSurg: 16.4 percent reported, 15.6 percent operational and 7.6 percent organic; Cardiovascular: 22.4 percent reported, 21.5 percent ...
  42. [42]
    SYNERGY™ XD Everolimus-Eluting Platinum Chromium Coronary ...
    SYNERGY XD is a bioabsorbable polymer (BP) drug-eluting stent designed for increased pushability, strength, and flexibility for optimal healing.
  43. [43]
    Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal ...
    The clinical restenosis rate was approximately 60% lower among patients with drug-eluting stents than among patients with bare-metal stents.
  44. [44]
    The SYNERGY Bioabsorbable Polymer (BP) Stent was Designed to ...
    It was designed to address the challenges associated with permanent polymer stents such as inflammation, neoatherosclerosis and late stent thrombosis.
  45. [45]
    Boston Scientific discontinues Acurate TAVR sales - MassDevice
    May 28, 2025 · Boston Scientific has discontinued global sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement (TAVR) systems.
  46. [46]
    ACURATE neo2 - Boston Scientific
    The ACURATE neo2 valve features Active PVseal™ technology, an extended sealing skirt, a radiopaque marker, and wide stabilization arches. It is CE-marked in ...
  47. [47]
    EMBLEM™ MRI S-ICD System - Boston Scientific
    As the world's only subcutaneous implantable cardioverter defibrillator, the EMBLEM S-ICD System protects patients from sudden cardiac arrest (SCA).Missing: Accolade | Show results with:Accolade
  48. [48]
    Features, Specifications - EMBLEM MRI S-ICD System
    Unlike TV-ICDs, the EMBLEM MRI S-ICD System leaves the heart and vasculature untouched, avoiding the risks and complications associated with transvenous leads.Missing: Accolade | Show results with:Accolade
  49. [49]
    Why S-ICD? - EMBLEM MRI S-ICD System - Boston Scientific
    The EMBLEM MRI S-ICD system is the first and only subcutaneous implantable defibrillator that has provided protection for over two decades.Missing: Accolade | Show results with:Accolade
  50. [50]
    Mortality Benefit Among Primary Prevention Implantable ...
    A Cox proportional hazard model estimated a 24.3% lower risk of all-cause mortality in patients when treated vs not treated with an ICD (HR: 0.757; 95% CI: ...
  51. [51]
    ACCOLADE™ Pacing Systems - Boston Scientific
    1.6 ampere-hour (Ah) EL batteries are labeled to last between 9.5 and 16.7 years. Automatic Daily Monitoring Offers automatic daily monitoring with the ...
  52. [52]
    BATTERY TECHNOLOGY - Boston Scientific
    Boston Scientific's new ACCOLADE MRI EL brings the industry's longest-lasting battery technology 1-5 with a 1.6 Ah battery capacity, resulting in exceptional ...
  53. [53]
    MODULAR ATP Study of the mCRM™ System Meets Primary Safety ...
    May 18, 2024 · "We saw excellent overall clinical performance of the mCRM System in this study, including a high rate of communication success from the S-ICD ...
  54. [54]
    What Is mCRM Therapy? - EMBLEM MRI S-ICD System
    The Modular CRM (mCRM) System is designed to help reduce the risk of TV leads while providing the option to pace or receive ATP for those who need it.Missing: Accolade | Show results with:Accolade
  55. [55]
    U.S. Interventional Cardiology Device Market | 2025-2031
    Aug 13, 2025 · Boston Scientific was the leading competitor in the U.S. interventional cardiology market in 2024, maintaining dominant positions in the ...
  56. [56]
    SpyGlass DS Clinical Data - Boston Scientific
    Rates of successful stone clearance using SpyGlass DS System–guided treatment ranged from 59% to 90%, and the overall clearance rate was 72% to 95%.23,26-29 ...
  57. [57]
    Boston Scientific Corporation SpyGlass(R) Direct Visualization ...
    Nov 2, 2011 · 92 percent procedural success for stone management; 71 percent of patients achieved complete stone clearance in one session. The study authors ...
  58. [58]
    GreenLight™ Laser Therapy - Boston Scientific
    2 When compared to traditional surgery, GreenLight Laser Therapy can provide several advantages including:²⁻⁷. Shorter hospital stay; Shorter catheterization ...Missing: LithoVue stones
  59. [59]
    GreenLight™ and TURP: The evolving gold standard in BPH treatment
    Oct 20, 2022 · GreenLight provides TURP-like durable outcomes and symptom improvement and noteworthy safety advantages, such as less bleeding, shorter hospital stays and a ...Missing: LithoVue | Show results with:LithoVue
  60. [60]
    LithoVue™ Elite - Next-Gen Ureteroscope - Boston Scientific
    Learn how the LithoVue Elite Single-Use Digital Flexible Ureteroscope with intrarenal pressure monitoring can help you see more, know more, and do more.
  61. [61]
    Female Pelvic Medicine Products - Boston Scientific
    Fueled by physician insights and feedback, the Ultra Sling Family is designed to improve provider experience through more precise sling placement.
  62. [62]
    3 innovative treatments for common women's health issues
    Jun 18, 2025 · Another option is the Axonics™ Sacral Neuromodulation (SNM) System. Once surgically inserted, a small implant sends mild electric impulses to ...
  63. [63]
    [PDF] 2023 Performance Report | Boston Scientific
    We recorded an 81% response rate and favorable scores for being treated with dignity and respect (88%), feeling a sense of belonging (84%) and recommending BSC ...Missing: controversies | Show results with:controversies
  64. [64]
    Vercise™ DBS System - Boston Scientific
    Vercise DBS is engineered for precise neural targeting to customize therapy for patients with Parkinson's disease.
  65. [65]
    Vercise Genus DBS System clinical data - Boston Scientific
    INTREPID clinical study is the first multi-center, prospective, double-blind, randomized controlled trial with sham control for DBS in Parkinson's disease.
  66. [66]
    Study Details | NCT02071134 | Registry of Deep Brain Stimulation ...
    ... Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP) ...<|separator|>
  67. [67]
    WaveWriter Alpha™ Spinal Cord Stimulator System - Boston Scientific
    The WaveWriter™ Alpha SCS System provides safe access to full-body MRI scans when used with specific components and the patient is exposed to the MRI ...
  68. [68]
    [PDF] FDA - Summary of Safety and Effectiveness Data (SSED)
    The SOLIS study was designed to evaluate the safety and effectiveness of Spinal Cord. Stimulation (SCS) in patients with chronic low back and/or leg pain who ...<|separator|>
  69. [69]
    O039 EVALUATING SCS AND MEDICAL MANAGEMENT FOR ...
    May 13, 2024 · SOLIS is a prospective, multicenter RCT that compares SCS (Wavewriter Systems [Boston Scientific]) versus CMM in patients with chronic low ...
  70. [70]
    Obsidio™ Conformable Embolic - Boston Scientific
    Obsidio Embolic is indicated for use in the embolization of hypervascular tumors and blood vessels to occlude blood flow for controlling bleeding/hemorrhaging.
  71. [71]
    FARAPULSE PFA Platform - Boston Scientific
    FARAPULSE™ PFA Platform redefines electrophysiology with predictable outcomes, streamlined workflow, and confidence in cardiac ablation.About PFA therapy · Products · PFA clinical data · Peer-to-peer experience
  72. [72]
    Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed ...
    Apr 24, 2025 · Study of FARAPULSE pulsed field ablation system achieves positive results in the treatment of persistent atrial fibrillation.
  73. [73]
    Randomized Comparison of Everolimus-Eluting and Sirolimus ...
    Mar 13, 2012 · The next second-generation drug-eluting stent, the everolimus-eluting stent, proved superior to the paclitaxel-eluting stent, with a lower rate ...
  74. [74]
    Evolution of Coronary Stent Platforms: A Brief Overview of ... - NIH
    Oct 24, 2023 · Everolimus and Zotarolimus are semi-synthetic agents that have the same mechanism of action as sirolimus but with enhanced lipophilic properties ...
  75. [75]
    Bioabsorbable Polymer Cardiac Stent System – SYNERGY Stent
    The SYNERGY Everolimus Eluting Stent System is a drug eluting stent technology featuring a bioabsorbable polymer to promote optimal healing.
  76. [76]
    About PFA therapy - Boston Scientific
    Unlike thermal cardiac ablation methods, pulsed field ablation (PFA) therapy uses short bursts of electrical pulses to treat atrial fibrillation (AFib).
  77. [77]
    Boston Scientific Initiates Trial to Evaluate Industry's First Modular ...
    Dec 2, 2021 · The EMPOWER MPS, which consists of a leadless pacemaker and delivery catheter, is designed to complement the S-ICD System by providing a modular ...
  78. [78]
    AVVIGO™+ Multi-Modality Guidance System - Boston Scientific
    AVVIGO™+ Multi-Modality Guidance System is a streamlined platform that enhances your intravascular imaging and physiology experience.Avvigotm + · Avvigo+ Mobile Cart · Ivus And Physiology With...
  79. [79]
    Artificial Intelligence in Intravascular Imaging for Percutaneous ...
    The AVVIGO+ Multi-Modality Guidance System (Boston Scientific) is an advanced platform that integrates high-definition IVUS (OptiCross) and comprehensive ...Avvigo+ Ivus System · Ultreon 2.0 Oct Imaging... · Gentuity Hf-Oct Imaging...<|separator|>
  80. [80]
    Subcutaneous Versus Transvenous Implantable Defibrillator Therapy
    Jun 3, 2022 · S‐ICD is clinically superior to TV‐ICD in terms of lead‐related complications while demonstrating comparable efficacy and safety.
  81. [81]
    2-Year Results From a Pooled Analysis of the IDE Study and ...
    The S-ICD annual mortality rate of 1.6% and 2-year mortality rate of 3.2% in the pooled data compares favorably with recent ICD trials. With controlled ...
  82. [82]
    a systematic review and meta-analysis - PMC - PubMed Central
    The results of our meta-analysis provide strong evidence supporting the beneficial effect of ICD-only therapy on survival of patients with LVEF ≤35% due to ...
  83. [83]
    Clinical Evidence and Publications on FARAPULSE PFA
    The ADVANTAGE AF phase I trial measured the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System for patients with drug refractory, ...
  84. [84]
    OPTION Randomized Clinical Trial - Boston Scientific
    The trial met the primary efficacy endpoint of all-cause mortality, stroke or systemic embolism at 36 months, with the WATCHMAN FLX device demonstrating ...<|separator|>
  85. [85]
    COMPARE clinical trial results - Boston Scientific
    Boston Scientific's Ranger Drug-Coated Balloon demonstrated near 90% primary patency at one year in two randomized controlled trials. Learn more here.
  86. [86]
    Clinical Data Reinforce Safety and Efficacy of Boston Scientific's ...
    Three-year results and two-year pooled analysis presented at ACC demonstrate continued positive outcomes for both PROMUS and TAXUS Stents.
  87. [87]
    ACURATE Clinical Data - Boston Scientific
    Conclusions: Short-term outcomes after TAVI using the Neo2 or Ultra THV were excellent and, overall, comparable. However, transvalvular gradients were lower ...
  88. [88]
    Boston Scientific (BSX) - Revenue - Companies Market Cap
    Current and historical revenue charts for Boston Scientific. As of October 2025 Boston Scientific's TTM revenue is of $18.49 Billion USD.Missing: 1992-2005 figures
  89. [89]
    MDT or BSX - With 39% Return Forecast, BSX Probably Deserves ...
    Medtronic is trading at a cheaper P/S valuation vs Boston Scientific but it makes sense to pay more for Boston Scientific for higher return. ; LTM Revenue, 34.2 ...
  90. [90]
    Boston Scientific (BSX) Market Cap & Net Worth - Stock Analysis
    Since December 1, 1998, Boston Scientific's market cap has increased from $10.63B to $149.82B, an increase of 1,309.09%. That is a compound annual growth rate ...
  91. [91]
    BSX (Boston Scientific) ROIC % - GuruFocus
    Rating 3.5 · Review by GuruFocusBoston Scientific's ROIC % is 9.25% (calculated using TTM income statement data). Boston Scientific generates higher returns on investment than it costs the ...
  92. [92]
    Boston Scientific EBITDA 2011-2025 | BSX - Macrotrends
    Boston Scientific 2023 EBITDA was 3.597B, a 23.4% increase from 2022. Boston Scientific 2022 EBITDA was 2.915B, a 9.55% increase from 2021. EBITDA can be ...
  93. [93]
    Boston Scientific Revenue 2011-2025 | BSX - Macrotrends
    Boston Scientific revenue for the twelve months ending September 30, 2025 was $19.351B, a 21.63% increase year-over-year. · Boston Scientific annual revenue for ...Missing: 1992-2005 | Show results with:1992-2005
  94. [94]
    Boston Scientific announces results for fourth quarter and full year ...
    Feb 5, 2025 · The company estimates net sales growth for the full year 2025, versus the prior year period, to be in a range of approximately 12.5 to 14.5 ...
  95. [95]
    https://www.nasdaq.com/articles/boston-scientific-beats-q3-earnings-raises-2025-view-stock
  96. [96]
    https://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR-V3/q3-2025-financial-operational-highlights.pdf
  97. [97]
    https://seekingalpha.com/article/4833080-boston-scientific-continuing-ma-playbook-as-organic-achievements-impress
  98. [98]
    https://fortune.com/company/boston-scientific/earnings/q3-2025/
  99. [99]
    https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/is-boston-scientifics-bsx-upbeat-2025-guidance-shifting-its
  100. [100]
    https://www.reuters.com/legal/litigation/boston-scientific-lifts-annual-profit-forecast-strong-demand-heart-devices-2025-10-22/
  101. [101]
    Boston Scientific to pay Nevro $85 mln to end pain treatment patent ...
    Aug 2, 2022 · Medical-device maker Boston Scientific Corp has agreed to pay Nevro Corp $85 million to settle their patent dispute over spinal-stimulation ...
  102. [102]
    Appeals Court Affirms That J&J Stents Infringe Boston Scientific Patent
    Mar 31, 2025 · The Court of Appeals upheld the District Court's decision that JNJ's Bx Velocity and Cypher Stent Systems infringe Boston Scientific's patent ...Missing: settlement | Show results with:settlement
  103. [103]
    Nevro and Boston Scientific Announce the Settlement of Their ...
    Aug 1, 2022 · Boston Scientific also will grant Nevro a worldwide, non-exclusive, non-transferable license under Boston Scientific's asserted patent families ...Missing: neuromodulation | Show results with:neuromodulation
  104. [104]
    Boston Scientific fined $42M in stent patent lawsuit - Fierce Biotech
    Feb 3, 2023 · Boston Scientific found guilty of infringing on drug-eluting stent patent, fined $42M. By Andrea Park Feb 3, 2023 11:17am.
  105. [105]
    Boston Scientific hit with $42M verdict in drug-eluting stents IP case
    Boston Scientific must pay $42 million in unpaid royalties to TissueGen and the University of Texas, a federal jury in Delaware has ruled.
  106. [106]
    Boston Scientific Announces Dismissal of Johnson & Johnson ...
    The Court dismissed Johnson & Johnson's lawsuit, found that the Company's NIR stent did not infringe one patent of Johnson & Johnson, and found that the other ...Missing: ICD settlement
  107. [107]
    Boston Scientific Announces Court Upholds Jury Verdict Against J&J
    The jury had also found the patent to be valid. "We are very pleased that the Court has upheld the jury's verdict in favor of Boston Scientific," said Paul ...Missing: Cordis win
  108. [108]
    FDA Issues Recall Notice for Boston Scientific's Obsidio ...
    Apr 17, 2024 · The FDA announced that Boston Scientific recalled its Obsidio conformable embolic for increased bowel ischemia risk when used for lower gastrointestinal (GI) ...Missing: 2019 | Show results with:2019
  109. [109]
    Boston Scientific blood-blocking agent tied to additional 2 deaths, 8 ...
    Oct 21, 2024 · After a February recall, Boston Scientific has warned physicians about new safety risks for Obsidio Embolic, which is now connected to a total of 15 injuries ...Missing: 2019 | Show results with:2019
  110. [110]
    Boston Scientific Updates Use Instructions for Obsidio Conformable ...
    Oct 18, 2024 · This recall involves updating instructions for using these devices and does not involve removing them from where they are used or sold.Missing: 2019 | Show results with:2019
  111. [111]
    Accolade Pacemaker Devices by Boston Scientific: Early Replacement
    Dec 16, 2024 · In addition, the manufacturer is developing a software update to detect battery health in all Accolade pacemaker devices. FDA Actions ...
  112. [112]
    Boston Scientific Recalls Accolade Pacemakers - FDA
    Mar 3, 2025 · This mode uses more power, decreases battery life and may cause incorrect battery life estimate. For patients with certain devices, who are ...
  113. [113]
    FDA details Class I recalls for more than 1 million pacemakers ...
    Oct 13, 2025 · The FDA has finalized new Class I recalls related to ongoing safety concerns with Boston Scientific's Accolade family of pacemakers.
  114. [114]
    Boston Scientific issues new notice on pacemaker software update
    Sep 11, 2025 · Boston Scientific has issued a notice to customers related to a previous recall of its Accolade pacemakers.
  115. [115]
    Update on Alert: Defibrillation Lead Issue from Boston Scientific - FDA
    Sep 12, 2025 · As of July 24, Boston Scientific has reported 386 serious injuries and 16 patient deaths associated with this issue. Device Use. Boston ...
  116. [116]
    FDA updates on Boston Scientific defibrillation lead recall
    Sep 15, 2025 · The FDA issued a correction related to a recall of Boston Scientific (NYSE:BSX) defibrillation leads, labeling it the most serious kind.
  117. [117]
    Rate and predictors of electrical failure in non-recalled defibrillator ...
    Dec 18, 2018 · Only 2.3% of non-recalled ICD leads experience electrical failure (annual failure rate of 0.6%). A higher patient functional status, lower BMI, ...
  118. [118]
    https://www.ahajournals.org/doi/10.1161/JAHA.115.002418
  119. [119]
    Risk of Failure of Transvenous Implantable Cardioverter-Defibrillator ...
    Apr 17, 2009 · The present study provides the long-term lead failure rate for 2161 defibrillation leads implanted in 2068 consecutive patients at a single ...
  120. [120]
    Boston Scientific Pays Million to Settle Defective Heart Defibrillator Suit
    Boston Scientific's latest $30 million settlement brings to $972 million the total amount the company has paid to resolve lawsuits and federal investigations.
  121. [121]
    Boston Scientific settlement of Guidant claims swells to $240M | wthr ...
    The new total covers more than some 8,500 claims involving Guidant implantable defbrillators that were subject to recalls and safety warnings in 2005 and 2006.
  122. [122]
    Boston Scientific and Subsidiaries to Pay $30 Million for Guidant's ...
    Oct 17, 2013 · (Guidant), have agreed to pay $30 million to settle allegations that, between 2002 and 2005, Guidant knowingly sold defective heart devices to ...
  123. [123]
    Damages slashed to $34.6 mln in Boston Scientific mesh trial | Reuters
    Oct 3, 2014 · A jury award of $73.4 million to a woman who said she was injured by a Boston Scientific Corp transvaginal mesh device has been cut to $34.6 ...
  124. [124]
    California Department of Justice Announces $188.6 Million Mu…
    Mar 23, 2021 · The settlement requires Boston to pay $188.6 million to 47 states and the District of Columbia to resolve allegations that it deceptively marketed transvaginal ...
  125. [125]
    Boston Scientific to Pay $296 Million Settlement for Guidant FDA ...
    Under the terms of the agreement, Guidant will plead to two misdemeanor charges related to failure to include information in reports to the U.S. Food and Drug ...Missing: litigation | Show results with:litigation
  126. [126]
    Boston Scientific Corporation - SEC.gov
    Michael F. Mahoney, age 52, joined the Company as our President in October 2011, and became our President and Chief Executive Officer and a director in November ...
  127. [127]
    Boston Scientific Names Michael F. Mahoney as Company ...
    In this role, which he held from 2007 through 2010, Mahoney drove a successful growth strategy via product innovation, multiple acquisitions, and international ...Missing: achievements | Show results with:achievements
  128. [128]
    Michael Mahoney Turned Boston Scientific Into A Medical Tech ...
    May 29, 2025 · Mahoney became CEO in November 2012. At that time, annual revenue was $7.3 billion and the company lost $4 billion. It would be an ...Missing: tenure achievements
  129. [129]
    Mike Mahoney Leads Boston Scientific into a New Era of Innovation
    Aug 5, 2025 · Under Mahoney's stewardship, Boston Scientific's annual revenue surged from $7.3 billion in 2012 to $16.7 billion by 2024 more than doubling in ...
  130. [130]
    Mike Mahoney - Chairman and CEO - Boston Scientific
    Boston Scientific is a global medical technology leader with approximately $16.7 billion in annual revenue and commercial representation in more than 127 ...Missing: tenure achievements growth
  131. [131]
    John Abele '59 | 2011 Honorees - Amherst College
    Abele co-founded Boston Scientific with Peter Nicholas in 1979, with the goal of developing technologies to make medical procedures less invasive and more ...
  132. [132]
    Boston Scientific co-founder, former CEO Peter Nicholas dies at 80
    May 16, 2022 · Peter Nicholas, who helped found Boston Scientific in 1979 and led the medtech giant as chief executive from then until 1999, died on May 14.
  133. [133]
    Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire
    Dan Brennan, executive vice president and chief financial officer, has elected to retire following nearly 30 successful years with the company.
  134. [134]
    Boston Scientific's long-term CFO to retire, senior vice president ...
    Apr 23, 2025 · After having served as CFO of Boston Scientific since 2014, Brennan will retire from his executive leadership roles at the end of June. While he ...
  135. [135]
    About Us - Our Mission And Values - Boston Scientific
    Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Professionals ...Locations · Core businesses · Leadership
  136. [136]
    Boston Scientific Mission, Benefits, and Work Culture | Indeed.com
    Core Values · Caring: We act with integrity and compassion to support patients, customers, our communities and each other. · Meaningful Innovation: · High ...Missing: organizational | Show results with:organizational
  137. [137]
    Empowered people - Boston Scientific
    Fostering an inclusive workplace. Diversity is a core value and the unique ideas, experiences and perspectives of our employees drive innovation.
  138. [138]
    Working at Boston Scientific | Glassdoor
    Rating 4.2 (6,721) Employees rate Boston Scientific 4.2 out of 5 stars based on 5,509 anonymous reviews on Glassdoor. In 2018, 2019, 2022 and 2024, Boston Scientific employees ...Reviews · Jobs · Salaries · InterviewsMissing: surveys | Show results with:surveys
  139. [139]
    [PDF] 2022 Performance Report - Boston Scientific
    Employee turnover or attrition rate. Percent. 11.9. 12.0. 10.3. 15.3. 15.1. Employee voluntary turnover rate. Percent. 9.5. 9.5. 7.1. 11.4. 12.3. Analysis not.
  140. [140]
    Boston Scientific Patents - Insights & Stats (Updated 2025)
    Aug 20, 2025 · Boston Scientific has a total of 49267 patents globally, out of which 26997 have been granted. Of these 49267 patents, more than 45% patents ...Missing: employee | Show results with:employee
  141. [141]
    Boston Scientific named to Fortune's America's Most Innovative ...
    Mar 25, 2024 · Today, Fortune announced that Boston Scientific was named to its America's Most Innovative Companies list for 2024.Missing: productivity patents per
  142. [142]
    Boston Scientific and the Road to Ruin
    Jun 21, 2011 · The company has paid the feds $22 million more to settle charges that Guidant sales representatives gave kickbacks to doctors who bought ...
  143. [143]
    Boston Scientific to Pay $30 Million in Healthcare Fraud Case | T
    Oct 24, 2013 · The Department of Justice announced last week that Boston Scientific Corp. and Guidant, a subsidiary of the company, will pay $30 million to ...Missing: issues incentives bribery
  144. [144]
    Boston Scientific says it's investigating allegations of anti-bribery law ...
    Aug 10, 2022 · Boston Scientific said it's investigating allegations of Foreign Corrupt Practices Act violations in Vietnam after receiving a whistleblower letter.
  145. [145]
    [PDF] Code of Conduct - Boston Scientific
    Our culture is based on a strong foundation of clear and simple values and behaviors which are the core of everything we do – externally and internally. Caring.<|separator|>
  146. [146]
    Compliance and ethics - Boston Scientific
    Boston Scientific aims to respond promptly and impartially to questions, concerns and reports of potential violations of our compliance program. We have ...Missing: incentives | Show results with:incentives
  147. [147]
    Global Locations - About Us - Boston Scientific
    Arden Hills, Minnesota 4100 Hamline Avenue North St. Paul, MN 55112-5798. Belo Horizonte Av. General David Sarnoff, 3445 – Cidade
  148. [148]
    All Jobs in Maple Grove, MN - Jobs at Boston Scientific
    Innovation happens here - explore All Jobs in Maple Grove, MN. Today, we're 24,000 colleagues strong, with an impressive portfolio of 13,000 products. We're at ...
  149. [149]
    https://www.cbsnews.com/minnesota/news/boston-scientific-opens-400000-square-foot-facility-in-maple-grove/
  150. [150]
    Boston Scientific announces €100m investment in Galway Campus
    Apr 14, 2022 · More than four million medical devices are exported from the Galway facility every year, including heart stents and valves, vascular balloons ...
  151. [151]
    [PDF] Our Approaches To A Resilient Supply Chain | Boston Scientific
    These detailed insights enable the work of our teams in more than 20 key global manufacturing and distribution ... • Manufacturing capacity and flexibility.
  152. [152]
    https://tcbmag.com/new-boston-scientific-arbor-lakes-facility-opens-in-maple-grove/
  153. [153]
    Overview - Boston Scientific
    We advance science for life. Boston Scientific innovations help address healthcare's greatest challenges, so patients can experience more of what truly matters.
  154. [154]
    Boston Scientific (BSX) Gains From Global Expansion, FX Woe Ails
    Dec 5, 2023 · Within the Asia Pacific (“APAC”), Boston Scientific is particularly registering strong growth in Japan and China. Within Japan, the company is ...
  155. [155]
    Boston Scientific Announces Strategic Investment to Acquire ...
    Dec 11, 2022 · Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of Acotec, a Chinese medical technology company.Missing: EMEA | Show results with:EMEA
  156. [156]
    HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS ...
    Outcomes from landmark trial show that, in heart attack (AMI) patients, drug-eluting stents were superior in efficacy to bare-metal stents. Learn more.Missing: mortality rates
  157. [157]
    Impact of stent length and diameter on 10-year mortality in ... - PubMed
    May 5, 2021 · Conclusions: Extensive and small stenting were associated with higher 10 year mortality, compared with CABG. When patients have to be treated ...
  158. [158]
    Global Expansion – Boston Scientific | Advancing Science For Life
    We see great opportunity in Emerging Markets 1 , which represented $1.25 billion in revenue in 2019, or 12 percent of annual sales.Missing: 1990s | Show results with:1990s